Early Detection Research Network


This biomarker is also known as:
  • ROMA,


The Risk of Ovarian Malignancy Algorithm (ROMA) algorithm was approved by the FDA in 2011. Research demonstrates that examining levels of HE4 and CA125 using the ROMA algorithm shows the highest accuracy in determining ovarian cancer risk in pre- and post-menopausal women who have an ovarian mass present.


There are no datasets associated with this biomarker.

QA State: Curated
HGNC Name:

Panel Details

The following organs have data associated with this biomarker…


Phase: Three
QA State: Under Review


The risk of malignancy algorithm (ROMA) includes CA125, human epididymal protein 4 (HE4) and menopausal status, but not imaging results.

Performance Comment

The risk of malignancy algorithm (ROMA) has yielded 93%-94% sensitivity at 75% specificity with a negative predictive value of 93%-98%. In a direct comparison, ROMA has achieved greater sensitivity (94%) than the RMI (75%) at 75% specificity. OVA1 has not been compared directly to ROMA, but is likely to be as sensitive, but substantially less specific.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.